Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
- DOI
- 10.1371/journal.pone.0200996
- Published
- 2018
- Container
- PloS one
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1371/journal.pone.0200996,
title = {Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).},
author = {Coté D and Eustace A and Toomey S and Cremona M and Milewska M and Furney S and Carr A and Fay J and Kay E and Kennedy S and Crown J and Hennessy B and Madden S},
year = {2018},
journal = {PloS one},
doi = {10.1371/journal.pone.0200996},
url = {https://doi.org/10.1371/journal.pone.0200996}
}RIS
TY - JOUR TI - Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). AU - Coté D AU - Eustace A AU - Toomey S AU - Cremona M AU - Milewska M AU - Furney S AU - Carr A AU - Fay J AU - Kay E AU - Kennedy S AU - Crown J AU - Hennessy B AU - Madden S PY - 2018 JO - PloS one DO - 10.1371/journal.pone.0200996 UR - https://doi.org/10.1371/journal.pone.0200996 ER -
APA
D, C., A, E., S, T., M, C., M, M., S, F., A, C., J, F., E, K., S, K., J, C., B, H., & S, M. (2018). Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).. PloS one. https://doi.org/10.1371/journal.pone.0200996
Source records
- pubmed · retrieved 2026-11-10T13:19:29.243Z